Related Experiment Videos

Re-processing of biological products: regulatory considerations from the CBER perspective

E Shacter1

  • 1Division of Therapeutic Proteins, CBER, FDA, Rockville, Maryland 20852, USA. shacter@cber.fda.gov

Developments in Biologicals
|November 19, 2003
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos